New lab model finally mimics the bone marrow scarring of myelofibrosis, pointing to SPP1 as a treatment target
Myelofibrosis (MF) is the most severe type of myeloproliferative neoplasm, characterized by scarring of the bone marrow that eventually destroys normal blood cell production. Current treatments rarely reverse this fibrosis, and progress has been hampered by a lack of good animal models.
New lab model finally mimics the bone marrow scarring of myelofibrosis, pointing to SPP1 as a treatment target
Myelofibrosis (MF) is the most severe type of myeloproliferative neoplasm, characterized by scarring of the bone marrow that eventually destroys normal blood cell production. Current treatments rarely reverse this fibrosis, and progress has been hampered by a lack of good animal models.
This study developed a 'humanized ossicle' model by transplanting human bone marrow stem cells (overexpressing thrombopoietin, THPO) into specially engineered bone-like structures in immunodeficient mice. The result was a convincing recapitulation of myelofibrosis features: progressive reticulin fibrosis, megakaryocyte clustering, abnormal blood cell distribution, and even osteosclerosis (abnormal bone hardening).
Using this model, researchers identified SPP1 (osteopontin) as a key player in the microenvironmental remodeling that drives fibrosis. This provides both a validated disease model for future drug testing and a potential new therapeutic target in myelofibrosis.
Key Findings
- THPO overexpression in human CD34+ cells induced progressive reticulin fibrosis in ossicle models
- Model faithfully reproduced myelofibrosis features including megakaryocyte clustering and extramedullary hematopoiesis
- Osteosclerosis — increased trabecular bone — was recapitulated in the humanized model
- SPP1 (osteopontin) was identified as a key regulator of microenvironmental remodeling in MF
- The humanized ossicle approach enables human-specific disease modeling for MF drug testing
Implications
This model fills a critical gap in myelofibrosis research by enabling human-relevant preclinical testing. SPP1 emerges as a potential therapeutic target that could address the fibrosis component of the disease — something current JAK inhibitor therapies largely fail to do.
Caveats
Preprint, not peer reviewed. Mouse models with humanized niches still have limitations in fully recapitulating human bone marrow biology. SPP1 findings need functional validation. Summary based on abstract only.
Source: bioRxiv — 2026-04-11
